Lu 177 dotatate therapy is a treatment modality used to manage and treat neuroendocrine tumor patients. This activity reviews the indications, action, and contraindications for Lu 177 dotatate therapy as a valuable agent in the management of neuroendocrine or carcinoid tumors. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of the interprofessional, multidisciplinary teams involved in managing patients with advanced neuroendocrine tumors.

**Objectives:**
- Identify disease-state information about neuroendocrine tumors and carcinoid syndrome.
- Outline the use of Lu 177 dotatate therapy to improve overall survival and progression-free survival in adults with unresectable, advanced, or well or moderately-differentiated neuroendocrine tumors.
- Review the clinical information on the safety and efficacy of Lu 177 dotatate therapy for treating neuroendocrine tumors in adults.
- Summarize the treatment modalities for carcinoid syndrome adult patients.